Leqembi has been approved in the European Union for the treatment of certain adults with early Alzheimer's disease and mild ...

Eisai Co.’s breakthrough Alzheimer’s drug Leqembi was cleared for use in the European Union, after the medicine was approved in the US and Japan. The European Commission approved the drug to treat ...

The Trump administration is expected to announce tariffs on pharmaceuticals "in the next month or two," an official said. | The Trump administration is expected to announce tariffs on pharmaceuticals ...

Leqembi approved by the EU for early-stage Alzheimer’s in patients with specific ApoE4 gene profile, marking a milestone in ...

Patients will lose access to cheaper versions of the blockbuster drugs after the agency shuts down the multibillion-dollar industry now that the drug shortage has ended. Also in the news: Eli Lilly's ...

Find insight on Abbott Laboratories, Sartorius and more in the latest Market Talks covering the Health Care sector.

The European Commission said Wednesday that it had given formal approval for Leqembi, a long-awaited new treatment for ...

Leqembi gains European approval after CHMP reversal, despite safety concerns tied to brain swelling and bleeding in Alzheimer ...

Biogen BIIB and partner Eisai announced that the European Commission (EC) has granted marketing authorization to Leqembi ...

European regulators have finally approved the Alzheimer’s treatment Leqembi after an advisory committee initially rejected ...

CHMP reversed its initial recommendation for the EC to not authorize the drug due to the risk of side effects like ARIA.

European regulators have approved Alzheimer's treatment Leqembi after initial rejection. The drug, from Eisai and Biogen, is ...